A phase 2 study of the dual SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma Meeting Abstract
| Authors: | Horwitz, S. M.; Feldman, T. A.; Hess, B. T.; Khodadoust, M. S.; Kim, Y. H.; Munoz, J.; Patel, M. R.; Phillips, T. J.; Smith, S. D.; Smith, S. M.; Wilcox, R. A.; Birrell, M. R.; Leeds, J. M.; Conley, P. B.; Michelson, G. C.; Coffey, G. P.; Curnutte, J. T.; Hamlin, P. A. |
| Abstract Title: | A phase 2 study of the dual SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Start Page: | 466 |
| Language: | English |
| ACCESSION: | WOS:000518218500569 |
| DOI: | 10.1182/blood-2019-123986 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 624 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work